ReviewCell metabolism2021
Diabetes, obesity, metabolism, and SARS-CoV-2 infection: the end of the beginning.
Review in Cell metabolism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 176 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
176 citing papers in PubMed, 4 syntheses or guidelines pooled it, 281 citations in OpenAlex.
- Diabetes Mellitus, a Leading Comorbidity in COVID-19: an Insight on Pathophysiology, Molecular Interactions, and Comprehensive Management.Current microbiology · 2025Pooled it
- Obesity as a clinical predictor for severe manifestation of dengue: a systematic review and meta-analysis.BMC infectious diseases · 2023Pooled it
- Glucocorticoid-Induced Hyperglycemia Including Dexamethasone-Associated Hyperglycemia in COVID-19 Infection: A Systematic Review.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2022Pooled it
- Prevalence and impact of diabetes in hospitalized COVID-19 patients: A systematic review and meta-analysis.Journal of diabetes · 2022Pooled it
- Changes in Glycemic Control and Lipid Profiles Following COVID-19 Infection in Adults with Type 2 Diabetes: A Retrospective Study in Saudi Arabia.Pathogens (Basel, Switzerland) · 2026Article
- SARS-CoV-2 and diabetes: a post-pandemic reappraisal.Diabetologia · 2026Review
- Article
- Epithelial TMPRSS2 impairs glucose homeostasis in obese mice by regulating ghrelin-GLP-1 receptor signaling pathway.JCI insight · 2026Article
- Burden and Outcomes of Viral Respiratory Infections Among Adults in Bahrain: A Retrospective Cohort Study.Cureus · 2026Article
- SARS-CoV-2 Spike Protein S2 Subunit: Recombinant Protein Expression Analysis, Purification, and Its Regulatory Effect on IGF-1R Expression.The protein journal · 2026Article
- The silent epidemic within the pandemic: pathophysiology and prediction of post-COVID-19 diabetes.Journal of translational medicine · 2026Review
- Assessment of biochemical and hematological profiles in outpatients with serological evidence of SARS-CoV-2 infection.Frontiers in medicine · 2026Article
- Endoplasmic reticulum stress in skeletal muscle dysfunction of type 2 diabetes: mechanisms and therapeutic implications.Frontiers in endocrinology · 2026Review
- Association between the glucose-to-lymphocyte ratio and prognosis in COVID-19 patients.Frontiers in cellular and infection microbiology · 2026Article
- Transcending risk factors: the implications of redefining diabetes as an immunometabolic disease for infectious disease studies.Frontiers in immunology · 2026Review
- Targeting Host Dependency Factors: A Paradigm Shift in Antiviral Strategy Against RNA Viruses.International journal of molecular sciences · 2025Review
- Body composition measurement and diabetes - A new perspective on development of antibodies after SARS-CoV-2 booster vaccination.Journal of diabetes and metabolic disorders · 2025Article
- Repeated Withdrawal of a GLPR Agonist Induces Hyperleptinemia and Deteriorates Metabolic Health in Obese Aging UM-HET3 Mice.Aging cell · 2025Article
- Review
- Severe and Intractable Hypokalemia in a Patient With New-onset Type 1 Diabetes and COVID-19 Infection.JCEM case reports · 2025Article
116 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The increased prevalence of obesity, diabetes, and cardiovascular risk factors in people hospitalized with severe COVID-19 illness has engendered considerable interest in the metabolic aspects of SARS-CoV-2-induced pathophysiology. Here, I update concepts informing how metabolic disorders and their co-morbidities modify the susceptibility to, natural history, and potential treatment of SARS-CoV-2 infection, with a focus on human biology. New data informing genetic predisposition, epidemiology, immune responses, disease severity, and therapy of COVID-19 in people with obesity and diabetes are highlighted. The emerging relationships of metabolic disorders to viral-induced immune responses and viral persistence, and the putative importance of adipose and islet ACE2 expression, glycemic control, cholesterol metabolism, and glucose- and lipid-lowering drugs is reviewed, with attention to controversies and unresolved questions. Rapid progress in these areas informs our growing understanding of SARS-CoV-2 infection in people with diabetes and obesity, while refining the therapeutic strategies and research priorities in this vulnerable population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.